Amplexd Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Amplexd Therapeutics is a private, pre-revenue biotech founded in 2020 and based in San Diego, CA. The company is focused exclusively on developing novel, non-invasive treatments for cervical dysplasia (CIN), the precursor to cervical cancer, using a combination of topical drug delivery and a proprietary cold-light photodynamic therapy device. Led by a co-founding team with deep expertise in pharmacology, product development, and medical device engineering, Amplexd aims to commercialize treatments that could reduce the need for surgical interventions like LEEP and cone biopsy. Its pipeline consists of two core programs targeting different grades of dysplasia, both currently in the pre-clinical development stage.

OncologyWomen's Health

Technology Platform

Integrated dual-modality system combining topical drug delivery (self-administered suppositories) and a proprietary cold-light photodynamic therapy (PDT) device for the non-invasive treatment of cervical dysplasia.

Opportunities

A large, global patient population with cervical dysplasia seeks alternatives to invasive surgical procedures like LEEP, representing a significant unmet medical need.

The growing focus on women's health and fertility preservation, alongside potential for improved access in low-resource settings with a reusable device, creates a favorable market environment for Amplexd's non-invasive solutions.

Risk Factors

The company faces high technical and clinical risk in proving the safety and efficacy of its novel integrated PDT system and suppository formulations.

Regulatory pathway for the combination product (drug+device) is complex and could be lengthy.

Market adoption may be slow as it requires changing the standard of care from established surgical procedures.

Competitive Landscape

The direct competitive landscape for non-invasive, non-thermal treatment of CIN2/3 is relatively sparse, with surgery as the dominant standard. However, Amplexd may face competition from other investigational topical therapies (e.g., immunomodulators) for low-grade lesions and from other ablation technologies (e.g., thermal, cryo) or larger pharma companies that may enter the space with systemic or localized therapies.

More companies in United States →